Moffitt Cancer Center Researchers Target Specific Protein Associated with Poor Survival and Treatment Resistance in Brain Cancer Patients

Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with low survival rates, with newly diagnosed patients surviving a median of 14 months and recurrent patients surviving a median of only three to nine months. New therapeutic targets and biomarkers for prognosis are urgently needed. Moffitt Cancer Center researchers recently reported that expression of the protein BIRC3 is associated with poor survival and recurrent disease in GBM patients; and therefore may be a good therapeutic t...
Source: National Comprehensive Cancer Network - Category: Cancer & Oncology Source Type: news